타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | enfortumab vedotin-ejfv (Padcev, ASG-22ME, enfortumab-vedotin-ejfv) Astellas / Pfizer (Seagen)·Nectin-4 201 trials | sacituzumab govitecan-hziy (Trodelvy, IMMU-132, sacituzumab-govitecan-hziy) Gilead / Immunomedics·TROP2 242 trials |
|---|---|---|
Overview Program | Padcev (enfortumab vedotin-ejfv) | Trodelvy (sacituzumab govitecan-hziy) |
Overview Company | Astellas / Pfizer (Seagen) | Gilead / Immunomedics |
Overview Modality | ADC | ADC |
Overview Target | Nectin-4 | TROP2 |
Overview Indication | Locally advanced or metastatic urothelial carcinoma | TNBC: regimen-specific first-line and previously treated indications; HR-positive/HER2-negative breast cancer after specified prior therapies. Consult current US label. |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved |
Positioning Key differentiator | Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue. | Very high DAR plus a deliberately unstable linker — extracellular SN-38 release gives bystander killing in TROP2-heterogeneous tumors. |
Positioning Known limitation | Nectin-4 loss, MMAE efflux, and tubulin alterations. | TROP2 downregulation, TOP1 mutation, and ABC-transporter payload efflux. |
Positioning Development positioning | 1L with pembrolizumab; monotherapy in later lines | Regimen-specific; includes 1L TNBC indications from June 2026 |
Technology Payload | MMAE (monomethyl auristatin E, tubulin inhibitor) | SN-38 (topoisomerase I inhibitor) |
Technology Linker | Protease-cleavable mc-vc-PAB, DAR ~3.8 | Hydrolyzable CL2A, DAR ~7.6 |
Technology DAR | DAR 3.8 | DAR 7.6 |
MoA Mechanism | Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis. | Anti-TROP2 antibody binds and internalizes; the hydrolyzable linker releases SN-38 both intracellularly and in the tumor microenvironment, inhibiting topoisomerase I and causing lethal DNA double-strand breaks. |
MoA Biomarker | Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required. | TROP2 is broadly expressed in epithelial tumors; no companion diagnostic is required in the label. |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, Hamster |
Toxicology Major finding | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Boxed warning for severe neutropenia and severe diarrhea. Nausea, alopecia, fatigue, and rare hypersensitivity are common. |
Toxicology CRS | N/A | N/A |
Clinical Safety signal | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Boxed warning for severe neutropenia and severe diarrhea. Nausea, alopecia, fatigue, and rare hypersensitivity are common. |
Clinical Selected reported efficacy | 95% | ORR 50% |
Clinical Reported ORR | — | 50% vs 47% (chemotherapy) |
Clinical Reported PFS | 12.5 months vs 6.3 months (platinum chemotherapy) | 9.7 months vs 6.9 months (chemotherapy) |
Clinical Reported OS | 31.5 months vs 16.1 months (platinum chemotherapy) | Immature in FDA approval analysis |
Clinical Result source | FDA approval report 2023-12-15 — EV-302 (NCT04223856) | FDA approval report 2026-06-24 — ASCENT-03 (NCT05382299) |
Clinical Program phase | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT04223856 | NCT05382299 |
Preclinical Animal (cat.) | — | Mouse |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | enfortumab vedotin-ejfv (Padcev, ASG-22ME, enfortumab-vedotin-ejfv) Astellas / Pfizer (Seagen)·Nectin-4 201 trials | sacituzumab govitecan-hziy (Trodelvy, IMMU-132, sacituzumab-govitecan-hziy) Gilead / Immunomedics·TROP2 242 trials |
|---|---|---|
Overview Program | Padcev (enfortumab vedotin-ejfv) | Trodelvy (sacituzumab govitecan-hziy) |
Overview Company | Astellas / Pfizer (Seagen) | Gilead / Immunomedics |
Overview Modality | ADC | ADC |
Overview Target | Nectin-4 | TROP2 |
Overview Indication | Locally advanced or metastatic urothelial carcinoma | TNBC: regimen-specific first-line and previously treated indications; HR-positive/HER2-negative breast cancer after specified prior therapies. Consult current US label. |
Overview Phase | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved |
Positioning Key differentiator | Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue. | Very high DAR plus a deliberately unstable linker — extracellular SN-38 release gives bystander killing in TROP2-heterogeneous tumors. |
Positioning Known limitation | Nectin-4 loss, MMAE efflux, and tubulin alterations. | TROP2 downregulation, TOP1 mutation, and ABC-transporter payload efflux. |
Positioning Development positioning | 1L with pembrolizumab; monotherapy in later lines | Regimen-specific; includes 1L TNBC indications from June 2026 |
Technology Payload | MMAE (monomethyl auristatin E, tubulin inhibitor) | SN-38 (topoisomerase I inhibitor) |
Technology Linker | Protease-cleavable mc-vc-PAB, DAR ~3.8 | Hydrolyzable CL2A, DAR ~7.6 |
Technology DAR | DAR 3.8 | DAR 7.6 |
MoA Mechanism | Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis. | Anti-TROP2 antibody binds and internalizes; the hydrolyzable linker releases SN-38 both intracellularly and in the tumor microenvironment, inhibiting topoisomerase I and causing lethal DNA double-strand breaks. |
MoA Biomarker | Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required. | TROP2 is broadly expressed in epithelial tumors; no companion diagnostic is required in the label. |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, Hamster |
Toxicology Major finding | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Boxed warning for severe neutropenia and severe diarrhea. Nausea, alopecia, fatigue, and rare hypersensitivity are common. |
Toxicology CRS | N/A | N/A |
Clinical Safety signal | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Boxed warning for severe neutropenia and severe diarrhea. Nausea, alopecia, fatigue, and rare hypersensitivity are common. |
Clinical Selected reported efficacy | 95% | ORR 50% |
Clinical Reported ORR | — | 50% vs 47% (chemotherapy) |
Clinical Reported PFS | 12.5 months vs 6.3 months (platinum chemotherapy) | 9.7 months vs 6.9 months (chemotherapy) |
Clinical Reported OS | 31.5 months vs 16.1 months (platinum chemotherapy) | Immature in FDA approval analysis |
Clinical Result source | FDA approval report 2023-12-15 — EV-302 (NCT04223856) | FDA approval report 2026-06-24 — ASCENT-03 (NCT05382299) |
Clinical Program phase | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT04223856 | NCT05382299 |
Preclinical Animal (cat.) | — | Mouse |
추천 비교
추천 비교